文献速递肝病

考来维仑通过调节粪便胆汁酸组成、信号传导与排泄减轻Mdr2-/-小鼠胆汁淤积性肝与胆管损伤

Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.
PubMed 文献 · Gut · 2018-04-10

在Mdr2-/-硬化性胆管炎小鼠模型中,考来维仑治疗8周可降低血清肝酶和胆汁酸、减少促炎与促纤维化标志物表达,增加粪便胆汁酸排泄并促进向次级胆汁酸转化,同时增加结肠GLP-1分泌及门静脉GLP-1水平,减轻肝与胆管损伤。

要点

  • 考来维仑降低Mdr2-/-小鼠血清肝酶、胆汁酸及促炎促纤维化标志物表达。
  • 考来维仑增加粪便胆汁酸排泄并促其转化为次级胆汁酸,肝与胆管胆汁酸向亲水性偏移。
  • 考来维仑增加结肠GLP-1分泌与门静脉GLP-1水平,并消除回肠Fgf15表达。

核心结论

  • 考来维仑增加粪便胆汁酸排泄并促进胆汁酸向次级胆汁酸转化,从而刺激肠道内分泌L细胞分泌GLP-1,减轻Mdr2-/-小鼠肝与胆管损伤。

研究设计与样本

  • Mdr2-/-小鼠接受考来维仑治疗8周,分析肝、肠、结肠基因表达、肝胆与粪便胆汁酸谱及肠道菌群,并用ELISA测门静脉血GLP-1。
  • Mdr2-/-小鼠及野生型3,5-二乙氧基羰基-1,4-二氢三甲基吡啶喂养小鼠接受GLP-1受体激动剂exendin-4治疗2周后分析。

主要发现

  • 考来维仑降低血清肝酶、胆汁酸及促炎与促纤维化标志物表达。
  • 粪便胆汁酸谱显示树脂治疗后次级胆汁酸水平增加,肝与胆管胆汁酸组成向更亲水性胆汁酸偏移。
  • 结肠GLP-1分泌、门静脉GLP-1水平及肠道促胰高血糖素原信使RNA表达增加,回肠Fgf15表达被考来维仑消除。
  • exendin-4治疗增加硬化性胆管炎小鼠模型的胆管质量,而未促进反应性胆管细胞表型。
  • 菌群分析显示考来维仑治疗后δ-变形菌门增加,厚壁菌门内由梭菌目向乳杆菌属偏移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Interruption of the enterohepatic circulation of bile acids (BAs) may protect against BA-mediated cholestatic liver and bile duct injury. BA sequestrants are established to treat cholestatic pruritus, but their impact on the underlying cholestasis is still unclear. We aimed to explore the therapeutic effects and mechanisms of the BA sequestrant colesevelam in a mouse model of sclerosing cholangitis. METHODS: Mdr2-/- mice received colesevelam for 8 weeks. Gene expression profiles of BA homeostasis, inflammation and fibrosis were explored in liver, intestine and colon. Hepatic and faecal BA profiles and gut microbiome were analysed. Glucagon-like peptide 1 (GLP-1) levels in portal blood were measured by ELISA. Furthermore, Mdr2-/- mice as well as wild-type 3,5-diethoxy-carbonyl-1,4-dihydrocollidine-fed mice were treated with GLP-1-receptor agonist exendin-4 for 2 weeks prior to analysis. RESULTS: Colesevelam reduced serum liver enzymes, BAs and expression of proinflammatory and profibrogenic markers. Faecal BA profiling revealed increased levels of secondary BAs after resin treatment, while hepatic and biliary BA composition showed a shift towards more hydrophilic BAs. Colonic GLP-1 secretion, portal venous GLP-1 levels and intestinal messenger RNA expression of gut hormone Proglucagon were increased, while ileal Fgf15 expression was abolished by colesevelam. Exendin-4 treatment increased bile duct mass without promoting a reactive cholangiocyte phenotype in mouse models of sclerosing cholangitis. Microbiota analysis showed an increase of the phylum δ-Proteobacteria after colesevelam treatment and a shift within the phyla Firmicutes from Clostridiales to Lactobacillus. CONCLUSION: Colesevelam increases faecal BA excretion and enhances BA conversion towards secondary BAs, thereby stimulating secretion of GLP-1 from enteroendocrine L-cells and attenuates liver and bile duct injury in Mdr2-/- mice.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Fuchs CD, Paumgartner G, Mlitz V, et al. Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids. Gut. 2018. PMID: 29636383. doi:10.1136/gutjnl-2017-314553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。